Exelixis/EXEL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Exelixis

Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Ticker

EXEL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Michael Morrissey

Employees

1,310

Headquarters

Alameda, United States

Exelixis Metrics

BasicAdvanced
$6.3B
Market cap
33.54
P/E ratio
$0.65
EPS
0.56
Beta
-
Dividend rate
$6.3B
0.55943
$24.34
$18.64
2.2M
3.465
3.408
27.867
6.90%
8.76%
7.82%
33.544
3.421
3.007
3.061
22.597
10.98%
36.97%
22.83%
22.51%

What the Analysts think about Exelixis

Analyst Ratings

Majority rating from 21 analysts.
Buy

Exelixis Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
8.77% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$425M
-11.34%
Net income
$37M
-56.37%
Profit margin
8.77%
-50.79%

Exelixis Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 49.65%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.25
-
$0.27
$0.12
-
Expected
$0.16
$0.10
$0.21
$0.24
$0.30
Surprise
56.25%
-
27.08%
-49.65%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Exelixis stock?

Exelixis (EXEL) has a market cap of $6.3B as of June 17, 2024.

What is the P/E ratio for Exelixis stock?

The price to earnings (P/E) ratio for Exelixis (EXEL) stock is 33.54 as of June 17, 2024.

Does Exelixis stock pay dividends?

No, Exelixis (EXEL) stock does not pay dividends to its shareholders as of June 17, 2024.

When is the next Exelixis dividend payment date?

Exelixis (EXEL) stock does not pay dividends to its shareholders.

What is the beta indicator for Exelixis?

Exelixis (EXEL) has a beta rating of 0.56. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Exelixis stock price target?

The target price for Exelixis (EXEL) stock is $26.55, which is NaN% below the current price of $. This is an average based on projections from 20 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Exelixis stock

Buy or sell Exelixis stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing